NEW DELHI: Any vaccine maker, including Pfizer, which has sought emergency-use authorisation for its Covid-19 shot in India, must conduct a local "bridging" safety and immunogenicity study to be considered for the country's immunisation programme, a senior government official told Reuters.
Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca and Oxford University, has done a similar study on more than 1,500 people over months before seeking and receiving emergency approval in the country.
According to reports, Pfizer had sought an exception when last month it became the first company to seek emergency-use approval in India for its vaccine already in use overseas. The company has not attended subsequent meetings called by India's drugs regulator.
"As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial," Vinod K Paul, who heads a government panel on vaccine strategy, said in an interview in his office near the parliament building.
A Pfizer spokeswomen did not immediately respond to a request seeking comment.
Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.
No vaccine maker will be given indemnity by the government should something go wrong, Paul said. Serum Institute had written to the government seeking indemnity. AstraZeneca has said it has received such indemnity in many other countries.
India has also approved for emergency use a vaccine developed locally by Bharat Biotech.
Serum Institute of India, the local manufacturer of the vaccine developed by AstraZeneca and Oxford University, has done a similar study on more than 1,500 people over months before seeking and receiving emergency approval in the country.
According to reports, Pfizer had sought an exception when last month it became the first company to seek emergency-use approval in India for its vaccine already in use overseas. The company has not attended subsequent meetings called by India's drugs regulator.
"As of now, the pre-condition for any vaccine to be implemented in India is that you have to do a bridging trial," Vinod K Paul, who heads a government panel on vaccine strategy, said in an interview in his office near the parliament building.
A Pfizer spokeswomen did not immediately respond to a request seeking comment.
Paul also said Russia's Sputnik V, a shot undergoing last-stage trials in India, will soon apply for emergency-use approval in the country.
No vaccine maker will be given indemnity by the government should something go wrong, Paul said. Serum Institute had written to the government seeking indemnity. AstraZeneca has said it has received such indemnity in many other countries.
India has also approved for emergency use a vaccine developed locally by Bharat Biotech.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
8 Comments on this Story
 | Kumar 1 day ago From various reports, it looks like that vaccines from PFIZER and MODERNA are more effective than others. Now, one has to see how India receives these two vaccines. |
| Sachin T1 day ago Ha ha ha .. India the banana republic and the typical bureaucracy. If they pay the right people they will get approval. |
 | Raj Sharlan1 day ago How many Baboo dom children are employed by Pfizer? |
